Morse Asset Management Inc Buys 259 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Morse Asset Management Inc increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,112 shares of the medical research company’s stock after buying an additional 259 shares during the period. Thermo Fisher Scientific accounts for about 1.9% of Morse Asset Management Inc’s portfolio, making the stock its 12th largest holding. Morse Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $7,621,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in TMO. Norges Bank acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $2,909,524,000. Capital World Investors increased its position in Thermo Fisher Scientific by 10.0% in the 1st quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock valued at $7,842,762,000 after acquiring an additional 1,231,059 shares during the period. International Assets Investment Management LLC increased its position in Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after acquiring an additional 1,008,045 shares during the period. Veritas Asset Management LLP increased its position in Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after acquiring an additional 697,383 shares during the period. Finally, Winslow Capital Management LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $333,786,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on TMO shares. Stifel Nicolaus upped their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Finally, Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $618.94.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 2.1 %

Shares of NYSE TMO traded up $12.64 during mid-day trading on Friday, hitting $607.14. 2,715,365 shares of the stock traded hands, compared to its average volume of 1,737,231. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.33 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $614.65. The company has a market cap of $231.76 billion, a price-to-earnings ratio of 38.94, a PEG ratio of 2.83 and a beta of 0.77. The stock has a fifty day moving average price of $563.01 and a 200-day moving average price of $565.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the company posted $5.15 earnings per share. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.